Nasdaq

Axonics® Announces U.S. Food & Drug Administration Approval of Wireless Patient Remote Control with SmartMRI Technology

IRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation ...
Nasdaq

Axonics® Announces Survey Results of Patients Treated with the Axonics r-SNM System That Were Previously Implanted with InterStim II

IRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation ...
Fast Company

Designing The Embarrassment Out Of Incontinence

Urinary dysfunction is one of those medical conditions that can be life-altering, especially because of the deep stigma associated with it. Current solutions are cumbersome and can be embarrassing.
Monthly Prescribing Reference

Sacral Neuromodulation Device Approved for OAB, Urinary Retention

The Axonics r-SNM System includes a neurostimulator, patented tined lead, remote control, and a charging system. The small, neurostimulator is implanted through a minimally invasive outpatient ...
MD&M East

Axonics Closes a Portfolio Gap in Sacral Neuromodulation

Competition in the sacral neuromodulation space continues to breed new options for patients with bladder and bowel dysfunction. Irvine, CA-based Axonics now has FDA approval for its recharge-free ...
FierceBiotech

Axonics nets FDA approval for its rechargeable sacral neuromodulation implant

Former FierceMedTech Fierce 15 winner Axonics Modulation Technologies has received FDA approval for its rechargeable neuromodulation implant to treat bowel dysfunction. According to the company, its r ...